ArticleCureus2025
Evaluating the Oncologic and Safety Outcomes of High-Dose Palliative Radiation Treatment with 30 Grays in Five Fractions.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction In select tumor sites, symptom palliation and local control can be improved through delivering higher biological equivalent doses (BED) of radiotherapy. However, not all patients are suitable candidates for stereotactic body radiation therapy (SBRT). The 30 Grays in five fractions (30/5) regimen is a conformal, hypofractionated regimen that offers a higher BED compared to conventional palliative radiotherapy. It adheres to the same organ-at-risk constraints as five-fraction SBRT. The planning and set-up processes are optimized to expedite treatment delivery compared to SBRT. This study aims to assess the oncologic and safety profiles of the 30/5 regimen. Methods Clinical data of patients who received the 30/5 regimen between October 2020 and August 2022 at our institution, the BC Cancer Vancouver Centre, were retrospectively reviewed. Local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), time to change in systemic therapy (CIS), and overall survival (OS) were calculated using the Kaplan-Meier method. Survival distributions between groups were compared using the log-rank test. Univariable and multivariable analyses were performed using Cox regression analysis to identify factors associated with the oncologic outcomes. Results Over 22 months, 77 patients received 92 courses of the 30/5 regimen. The median age was 68 years. The median tumor size treated was 11.4 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.